Insat Pharma Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
- Paid Up Capital ₹ 5.00 Cr
- Company Age 2 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
About Insat Pharma
Insat Pharma Private Limited (IPPL) is a Private Limited Indian Non-Government Company incorporated in India on 09 March 2022 (Two years and ten months 25 days old ). Its registered office is in Ahmedabad, Gujarat, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 5.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Hardik Patel, Nilesh Shah, Lal Hingorani, and Two other members serve as directors at the Company.
Company Details
-
Location
Ahmedabad, Gujarat, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24230GJ2022PTC129967
-
Company No.
129967
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
09 Mar 2022
-
Date of AGM
23 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Insat Pharma?
Board Members (5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Lal Hingorani
|
Director | 30-May-2022 | Current |
|
Hardik Patel
|
Director | 30-May-2022 | Current |
|
Nilesh Shah
|
Director | 09-Mar-2022 | Current |
|
Kruti Shah
|
Director | 09-Mar-2022 | Current |
|
Brijesh Patel
|
Director | 30-May-2022 | Current |
Financial Performance of Insat Pharma.
Insat Pharma Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Insat Pharma?
In 2023, Insat Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Shellac And Forest Products Export Promotion CouncilLal Hingorani is a mutual person
-
Pharmanza Herbal Private LimitedHardik Patel and Lal Hingorani are mutual person
-
Shree Hospitality Private LimitedHardik Patel is a mutual person
-
Pharmanza (India) Private LimitedHardik Patel, Lal Hingorani and 1 more are mutual person
-
Asn Hotel Llp
Hardik Patel is a mutual person
-
Atlas Cables And Accessories Private Limited
Hardik Patel is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Insat Pharma?
Unlock and access historical data on people associated with Insat Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Insat Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Insat Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.